OrbiMed and Third Rock’s Terremoto Biosciences raises $175M for small molecule R&D
Terremoto Biosciences has reeled in $175 million to create small molecules based on work from Principia Biopharma co-founder Jack Taunton and Global Blood Therapeutics co-founder Matthew Jacobson.
The Series B arrives 18 months after the South San Francisco biotech emerged with $75 million from OrbiMed and Third Rock Ventures. Thursday’s financing is another sign that Third Rock is doubling down on select companies in its portfolio, with Rapport Therapeutics bagging two nine-figure rounds this year and CARGO Therapeutics planning an IPO less than 12 months after its big unveiling.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
